Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
101 patients with locally aggressive erHCC were enrolled.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
34.0%, = 0.159). [CONCLUSION] Compared with HAIT alone, HAIT-M-P was associated with improved PFS and tumor response rates, and showed a possible trend toward improved OS in patients with locally aggressive erHCC, which warrants further validation.
[BACKGROUND] Current treatment strategies for locally aggressive (beyond Milan criteria), early recurrent hepatocellular carcinoma (erHCC) lack consensus.
- 표본수 (n) 51
- HR 0.36
APA
Luo W, Liu L, et al. (2025). Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.. Frontiers in immunology, 16, 1643082. https://doi.org/10.3389/fimmu.2025.1643082
MLA
Luo W, et al.. "Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.." Frontiers in immunology, vol. 16, 2025, pp. 1643082.
PMID
41019079 ↗
Abstract 한글 요약
[BACKGROUND] Current treatment strategies for locally aggressive (beyond Milan criteria), early recurrent hepatocellular carcinoma (erHCC) lack consensus. This study aims to compare the efficacy of hepatic arterial interventional therapies (HAIT) combined with molecular targeted therapies and PD-(L)1 inhibitors (HAIT-M-P) versus HAIT alone for locally aggressive erHCC.
[METHODS] This study retrospectively reviewed the data of locally aggressive erHCC patients treated with HAIT alone or HAIT-M-P at Sun Yat-sen University Cancer Center from 2020 to 2024. The progression-free survival (PFS), overall survival (OS), tumor responses, and treatment-related adverse events (TRAEs) were compared. Propensity score matching (PSM) and multivariate Cox regression model were used to minimize confounding bias.
[RESULTS] A total of 101 patients with locally aggressive erHCC were enrolled. Compared with the HAIT group (n=51), the HAIT-M-P group (n=50) demonstrated significantly longer median PFS (10.1 months vs. 3.7 months, HR = 0.36, < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.45, = 0.065). After PSM, 24 pairs of patients were included. The HAIT-M-P group maintained a significant median PFS advantage (12.8 months vs. 3.7 months, HR = 0.28, < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.56, = 0.330). In the multivariate Cox regression analysis, the HAIT-M-P group demonstrated a significant improvement in OS (HR = 0.30, = 0.033). The objective response rate and disease control rate were significantly higher in the HAIT-M-P group than in the HAIT group, respectively, according to the RECIST v1.1 (30.0% vs. 7.8%, = 0.009; 82.0% vs. 54.9%, = 0.007) and mRECIST criteria (56.0% vs. 19.6%, < 0.001; 90.0% vs. 58.8%, = 0.001). The grade 3 - 4 TRAEs between the two groups were comparable (19.6% vs. 34.0%, = 0.159).
[CONCLUSION] Compared with HAIT alone, HAIT-M-P was associated with improved PFS and tumor response rates, and showed a possible trend toward improved OS in patients with locally aggressive erHCC, which warrants further validation.
[METHODS] This study retrospectively reviewed the data of locally aggressive erHCC patients treated with HAIT alone or HAIT-M-P at Sun Yat-sen University Cancer Center from 2020 to 2024. The progression-free survival (PFS), overall survival (OS), tumor responses, and treatment-related adverse events (TRAEs) were compared. Propensity score matching (PSM) and multivariate Cox regression model were used to minimize confounding bias.
[RESULTS] A total of 101 patients with locally aggressive erHCC were enrolled. Compared with the HAIT group (n=51), the HAIT-M-P group (n=50) demonstrated significantly longer median PFS (10.1 months vs. 3.7 months, HR = 0.36, < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.45, = 0.065). After PSM, 24 pairs of patients were included. The HAIT-M-P group maintained a significant median PFS advantage (12.8 months vs. 3.7 months, HR = 0.28, < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.56, = 0.330). In the multivariate Cox regression analysis, the HAIT-M-P group demonstrated a significant improvement in OS (HR = 0.30, = 0.033). The objective response rate and disease control rate were significantly higher in the HAIT-M-P group than in the HAIT group, respectively, according to the RECIST v1.1 (30.0% vs. 7.8%, = 0.009; 82.0% vs. 54.9%, = 0.007) and mRECIST criteria (56.0% vs. 19.6%, < 0.001; 90.0% vs. 58.8%, = 0.001). The grade 3 - 4 TRAEs between the two groups were comparable (19.6% vs. 34.0%, = 0.159).
[CONCLUSION] Compared with HAIT alone, HAIT-M-P was associated with improved PFS and tumor response rates, and showed a possible trend toward improved OS in patients with locally aggressive erHCC, which warrants further validation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Hepatocellular
- Liver Neoplasms
- Male
- Female
- Middle Aged
- Retrospective Studies
- Aged
- Neoplasm Recurrence
- Local
- Immune Checkpoint Inhibitors
- Molecular Targeted Therapy
- Adult
- Hepatic Artery
- B7-H1 Antigen
- Combined Modality Therapy
- Treatment Outcome
- Milan criteria
- early recurrence
- hepatic arterial interventional therapy
- hepatocellular carcinoma
- immune checkpoint inhibitor
- molecular targeted therapy
같은 제1저자의 인용 많은 논문 (5)
- Construction of Hollow Mesoporous Selenium Loaded With Carboplatin and Clacked With Bevacizumab-Functionalized Albumin Nanoparticles for HER2+ Lung Cancer.
- Integrated Transcriptomics Reveals a SHEV ORF3-Mediated circRNA Network That Disrupts Riboflavin Metabolism and Activates the ko05212 Pathway.
- On-Chip Microfluidic Production of Sonosensitizer-Loaded Liposomes for Sonodynamic Therapy of Hepatocellular Carcinoma.
- Validation of Chinese medicine syndrome differentiation in early breast cancer: a multicenter prospective clinical study.
- Percutaneous thermal ablation-based locoregional treatment for hepatocellular carcinoma larger than 3 cm: a 10-year single-center retrospective study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.